Home >

Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
A recent study should serve as a wake-up call to all Americans that obesity is linked to an increased risk of common cancers.
ASCO’s Clinical Cancer Advances report, our 14th edition, examines the most transformative research of the past year and offers our vision for future research priorities.
Predictive analytics, complex treatment pathways, tele-oncology, and more: Dr. Robert M. Daly identifies five trends that are poised to disrupt oncology practice in the coming year.
Social injustice is perpetuated when patients can't afford to participate in essential clinical research.
GLOBOCAN 2018 indicates a significant global increase in the numbers, incidence, and mortality rates, albeit significant differences in mortality amongst countries of different economic levels. 
ASCO's nearly 45,000 members practice in more than 150 countries, and continued progress against cancer will require every one of us, writes ASCO CMO Dr. Richard L. Schilsky.
Broadening eligibility critera for cancer clinical trials will give more patients the opportunity to contribute to scientific research.
ASCO CMO Dr. Richard L. Schilsky invites all cancer researchers to come together for education and networking around cancer clinical trials.
Dr. Arjun Gupta reconsidered an order (and the evidence) for a neutropenic diet when it negatively affected his patient's quality of life.  
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and approval of new therapies should be applauded. 
Dr. Edward S. Kim encourages you to register today and join the Research Community Forum in September for 2 days of learning and collaboration.
As the NSABP celebrates its 60th anniversary in 2018, Dr. Harry D. Bear honors the organization's history and accomplishments.
Clinical trials are the pathway to better treatments, better outcomes, and a future without cancer. We, as investigators, need to believe in them, and be willing to offer them to all patients who are eligible. 
ASCO's current president explains why he's passionate about precision medicine, as well as the concerns that keep him up at night. 
A trial of aqueous lidocaine to manage painful intercourse for breast cancer survivors was a small study with a great magnitude of benefit. Do we need to wait for more data, or can we start applying these findings for our patients today?
Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.

Pages


Advertisement